Filings
Finds words inside filing documents. Searching Evolus, Inc.'s filings · 34 documents indexed.
17 documents · 155 matches
-
EOLS Evolus, Inc. 10-Q 2025-11-05
Item 1A. Risk Factors
tariffs in the United States or retaliatory tariffs in response to such have caused an increase in our cost of goods16 matches in this document -
EOLS Evolus, Inc. 10-Q 2025-08-05
Item 1A. Risk Factors
tariffs in the United States or retaliatory tariffs in response to such have caused an increase in our cost of goods11 matches in this document -
EOLS Evolus, Inc. 10-Q 2026-11-04
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
tariff. On July 24, 2026 those tariffs expired, and were replaced by a new 10% tariff on Evolysse® under Section28 matches in this document -
EOLS Evolus, Inc. 10-Q 2026-05-04
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
implemented new tariffs to replace certain of the IEEPA tariffs. We are pursuing potential refunds of previously paid IEEPA tariffs.23 matches in this document -
EOLS Evolus, Inc. 10-K 2026-03-03
Item 1A. Risk Factors.
tariffs in the United States or retaliatory tariffs in response to such have caused an increase in our cost of goods17 matches in this document -
EOLS Evolus, Inc. 10-Q 2025-05-07
Item 1A. Risk Factors
tariff environment is dynamic and uncertain, as the U.S. government has imposed, modified and paused tariffs multiple times since the beginning6 matches in this document -
EOLS Evolus, Inc. 10-Q 2026-08-05
Item 1A. Risk Factors
tariffs on certain imports of patented pharmaceuticals and related ingredients, including tariffs of up to 100% (currently 15% with respect29 matches in this document -
EOLS Evolus, Inc. 8-K 2026-05-04
tariff on patented pharmaceuticals from South Korea. Absent an exception, this tariff would apply to Jeuveau® beginning September 29, 2026. Given4 matches in this document -
EOLS Evolus, Inc. 8-K 2026-03-03
tariff. The administration has also communicated the possibility of an additional 5% tariff, which has not been formally implemented. The Company3 matches in this document -
EOLS Evolus, Inc. 8-K 2025-11-05
tariffs for pharmaceuticals, the impact on Jeuveau® is still being evaluated pending additional guidance provided by the administration. Current inventory5 matches in this document -
EOLS Evolus, Inc. 8-K 2026-11-04
tariffs. As previously noted, Evolysse®, which is classified as a medical device and imported from France, remains subject to a 10% tariff4 matches in this document -
EOLS Evolus, Inc. 8-K 2025-08-05
purchases as the company pulled forward product ahead of increased tariffs on the European Union and threatened tariffs on pharmaceuticals.3 matches in this document -
EOLS Evolus, Inc. 8-K 2026-08-05
approximately 120 basis points from a tariff refund recognized during the quarter. Adjusted gross profit margin excludes amortization of intangible assets.2 matches in this document -
EOLS Evolus, Inc. 8-K 2026-08-04
tariffs and regulatory actions on imports, uncertainties related to customer and consumer adoption of Jeuveau® and Estyme®/Evolysse®, the efficiency1 match in this document -
EOLS Evolus, Inc. 8-K 2026-07-08
tariffs and regulatory actions on imports, uncertainties related to customer and consumer adoption of Jeuveau® and Estyme®/Evolysse®, the efficiency1 match in this document -
EOLS Evolus, Inc. 8-K 2026-01-09
tariffs and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency1 match in this document -
EOLS Evolus, Inc. 8-K 2025-05-27
tariffs and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau® and Evolysse™, the efficiency1 match in this document
Page 1 of 1 · 17 documents